Scopio Labs Funding, Investors & Competitors

Scopio Labs has raised $125M across 5 funding rounds, most recently a $10M Series D in July 2025.

Last Scopio Labs funding round

$10M

Series D · Jul 2025

Cumulative funding Scopio Labs raised

$125M

across 5 funding rounds

Key investors in Scopio Labs

Scopio Labs Overview

About Scopio Labs

Scopio Labs is a Tel Aviv-headquartered provider of full-field digital morphology systems for hematology. The platform uses AI to analyze high-resolution images from blood samples and bone marrow aspirates, revealing thousands of cells for advanced diagnostic insights. Scopio enables hematologists to uncover previously inaccessible data patterns in routine samples.


Founded

2015

HQ

IsraelTel Aviv

Status

Privately held

Customer focus

B2B

Revenue model

Product sales, Subscription

Scopio Labs Funding History

Scopio Labs has raised a total of $125M across 5 funding rounds.

Scopio Labs' first fundraising round was a $7M Series A in May 2017. The most recent completed round was a $10M Series D in July 2025.

Scopio Labs funding rounds

Scopio Labs funding rounds
DateStageInvestorsRaisedDeal Summary
Jul 2025Series DViola Growth (lead)$10MScopio Labs develops Full-Field Digital Cell Morphology imaging and analysis platforms for hematology diagnostics, using computational photography and AI to provide high-resolution digital imaging of blood cells, replacing manual microscopy. The company secured an additional $10 million from Viola Growth in July 2025, extending its Series D round to a total of $52 million, to accelerate rollout of its AI-powered Complete Blood Morphology (CBM) analyzer. This funding supports advancement of automated hematology processes from complete blood count to final results, with the CBM system examining 10x more cells than traditional methods for standardized lab processes. Earlier, Scopio completed the initial Series D tranche of $42 million led by Fortissimo Capital in July 2024, bringing total fundraising to $130 million, focused on commercial growth and product innovation. The company has CE and FDA clearance for its digital imaging platforms and plans to present the CBM analyzer at the ADLM 2025 conference.
Jul 2024Series DFortissimo Capital (lead)$42MScopio Labs completed a $42 million Series D funding round led by Fortissimo Capital in July 2024, bringing total fundraising to $130 million. The company, founded in 2015 by Itai Hayut (CEO) and Erez Naaman (CTO), develops full-field digital cell morphology imaging and analysis platforms that use computational photography to automate and digitize blood cell analysis. The platform delivers high-resolution imaging at 100X magnification combined with clinical AI-based decision support, replacing traditional manual microscopy in hematology laboratories. Founded in Israel with 110 employees, Scopio's technology addresses a fundamental limitation of manual microscopy by providing unprecedented field of view while maintaining resolution, enabling remote consultation, accelerating diagnostic decision-making, and reducing operational costs. The Series D funding was designated to accelerate commercial expansion, scale sales and marketing efforts, strengthen customer support, and advance development of next-generation products for hematology laboratories and hospitals worldwide.
Feb 2022Series COurCrowd (lead); Lumir Ventures; Mivtach Shamir Holdings; LR Group; Aurum Ventures MKI; Mizrahi-Tefahot Bank; Ilex Medical; OTV$50MScopio Labs develops Full-Field Digital Cell Morphology imaging and analysis platforms using computational photography for digital imaging of thousands of cells, enabling AI-based decision support in blood cell analysis to improve workflow efficiency, remote collaboration, and patient care in hematology labs. The company has raised funds across multiple rounds, including a Series A in 2017 with $7M (OurCrowd investing $2.5M), Series B in February 2022 led by Olive Tree Ventures with participation from Aurum Ventures, OurCrowd, LR Group, and others for $16M (total funding then $30M), a Debt round of $15M on September 28, 2022 from Kreos Capital, Series C in April 2020, and a Series D of $42M in July 2024 led by Fortissimo Capital bringing cumulative fundraising to $130M. Investors in Scopio include Aurum Ventures MKI, Ilex Medical, LR Group, Lumir Ventures (possibly Olive Tree Ventures), Mivtach Shamir Holdings, Mizrahi-Tefahot Bank, OTV, and OurCrowd as a recurring participant. Recent funding supports commercial expansion, sales scaling, and product innovation amid growing adoption in digital cell morphology.
Apr 2020Series BOTV (lead); LR Group; OurCrowd$16MScopio Labs, an advanced digital microscopy company based in Tel Aviv, Israel, completed a $16 million Series B funding round on April 28, 2020, led by Olive Tree Ventures (OTV) with participation from Aurum Ventures, OurCrowd, LR Group, and others. This brought the company's total funding to $30 million at that time. The round supported expansion of commercial operations in human and veterinary care across the United States and Europe, including ramping up manufacturing and sales, and developing a clinical trial pipeline. The funding followed receipt of CE mark certification for its X100 Full Field Peripheral Blood Smear microscopy system, an automated in-vitro hematology diagnostic platform with computer-vision-based decision support for remote consultation. Earlier that year, Scopio launched ScopioVet, a digital cytology solution for veterinary professionals. The company provides AI-based decision support and remote collaboration tools in hematology, pathology, research, and veterinary medicine.
May 2017Series AOurCrowd (lead)$7MScopio Labs, an Israeli healthtech startup founded in 2014 or 2015 by CEO Itai Hayut and Erez Na’aman, develops advanced digital microscopy platforms and diagnostics tools based on computational imaging breakthroughs. The company creates next-generation digital microscopes and image analysis software for applications in cancer, hematology, cytology, academic research, and drug discovery. Its technology enables high-resolution scans of lab slides for remote sharing among researchers. In May 2017, Scopio Labs raised $7 million in a financing round, with OurCrowd investing $2.5 million as the lead investor, marking OurCrowd’s 23rd healthtech investment and bringing its total healthcare portfolio to $80 million. The funds supported team expansion in Tel Aviv, including hires for computer vision experts, physicists, and software developers. OurCrowd CEO Jon Medved highlighted Scopio’s revolutionary impact on digital microscopy and patient care transformation.

Who has invested in Scopio Labs?

10 investors have backed Scopio Labs across its funding rounds, including OurCrowd, OTV, LR Group, Viola Growth, Fortissimo Capital and Mivtach Shamir Holdings.

Lead investors include Viola Growth, Fortissimo Capital, OurCrowd and OTV.


Scopio Labs Investors

Investors in Scopio Labs by funding rounds participated
InvestorHQRoundsRoleFirst check
OurCrowdIsraelJerusalem3LeadMay 2017
LR GroupIsraelHerzliya2ParticipantApr 2020
OTVIsraelIsrael2LeadApr 2020
Viola GrowthIsraelHerzliya1LeadJul 2025
Fortissimo CapitalIsraelTel Aviv1LeadJul 2024
Lumir VenturesAustraliaMelbourne1ParticipantFeb 2022
Mivtach Shamir HoldingsIsraelIsrael1ParticipantFeb 2022
Aurum Ventures MKIIsraelRamat Gan1ParticipantFeb 2022

This data is available for Pro users. Sign up to see all 10 Scopio Labs investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Scopio Labs Competitors

Scopio Labs competitors include listed companies like Tempus AI and SAP, and private ones like Sword Health, Commure, Abridge and EliseAI.

Public and private companies comparable to Scopio Labs
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Sword HealthUnited StatesNew York City, NYPrivate$240M-$4B16.7x
Tempus AIUnited StatesUnited StatesPublicly listed$1.3B($131M)$15B10.1x
CommureUnited StatesSan Francisco, CAPrivate$200M-$7B35.0x
AbridgeUnited StatesPittsburgh, PAPrivate$117M-$5.3B45.3x
EliseAIUnited StatesNew York City, NYPrivate$100M-$2.2B22.0x
SAPGermanyGermanyPublicly listed$42B$13B$248B5.4x

Scopio Labs Public Comps

Scopio Labs is still privately-owned, but its public comps include CrowdStrike, SAP, Thermo Fisher Scientific, Salesforce, Danaher, ServiceNow, Snowflake, Adobe, Datadog and Moody's.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
CrowdStrike$4.8B($12M)51.4x44.5x(19816.2x)151.0x
SAP$42B$13B5.8x5.4x18.4x17.1x
Thermo Fisher Scientific$45B$11B6.3x6.0x26.8x23.6x
Salesforce$42B$13B5.5x5.2x17.8x12.2x
Danaher$25B$6.9B7.0x6.6x24.8x21.1x
ServiceNow$13B$2.6B11.1x9.6x57.2x25.0x
Snowflake$4.7B($1.3B)25.6x21.0x(94.1x)121.7x
Adobe$24B$9.3B4.3x3.9x10.9x8.2x

This data is available for Pro users. Sign up to see all Scopio Labs competitors and their valuation data.

Start Free Trial

Common questions about Scopio Labs

When was Scopio Labs founded?Scopio Labs was founded in 2015.
Where is Scopio Labs headquartered?Scopio Labs is headquartered in Tel Aviv, Israel.
Is Scopio Labs publicly listed?No, Scopio Labs is a private, VC-backed company.
How much funding has Scopio Labs raised?Scopio Labs has raised $125M across 5 funding rounds.
What was Scopio Labs' last funding round?Scopio Labs' last funding round was a $10M Series D in July 2025, led by Viola Growth.
Who are Scopio Labs' investors?Scopio Labs' investors include OurCrowd, LR Group, OTV, Viola Growth, Fortissimo Capital, Lumir Ventures, Mivtach Shamir Holdings, Aurum Ventures MKI, Mizrahi-Tefahot Bank and Ilex Medical.
Which companies are comparable to Scopio Labs?Companies comparable to Scopio Labs include Sword Health, Tempus AI, Commure, Abridge, EliseAI and SAP.

See companies similar to Scopio Labs

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial